Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v13-FR | Version v7-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2022-01-06 | 2021-11-02 |
| Drug Identification Number | 02139561 | 02139561 |
| Brand name | OXYTOCIN INJECTION, USP | OXYTOCIN INJECTION, USP |
| Common or Proper name | Oxytocin Injection, USP Synthetic 10 USP units/mL SD Vial 1 mL | Oxytocin Injection, USP Synthetic 10 USP units/mL SD Vial 1 mL |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | OXYTOCIN | OXYTOCIN |
| Strength(s) | 10UNIT | 10UNIT |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR | INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR |
| Packaging size | 1 mL | 1 mL |
| ATC code | H01BB | H01BB |
| ATC description | POSTERIOR PITUITARY LOBE HORMONES | POSTERIOR PITUITARY LOBE HORMONES |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | 2021-11-01 | 2021-11-01 |
| Actual start date | 2021-11-01 | |
| Estimated end date | 2022-01-01 | 2022-01-30 |
| Actual end date | 2022-01-01 | |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Allocation strategy implemented to stretch inventory and ensure equitable distribution. Please see customer communication. | Allocation strategy implemented to stretch inventory and ensure equitable distribution. Please see customer communication. |
| Health Canada comments |